These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34883296)

  • 1. Outcomes associated with tocilizumab with or without corticosteroid versus dexamethasone for treatment of patients with severe to critical COVID-19 pneumonia.
    AlQahtani H; AlBilal S; Mahmoud E; Aldibasi O; Alharbi A; Shamas N; Alsaedy A; Owaidah K; Alqahtani FY; Aleanizy FS; Arishi H; Baharoon S; Bosaeed M
    J Infect Public Health; 2022 Jan; 15(1):36-41. PubMed ID: 34883296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
    Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
    JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
    Birlutiu V; Birlutiu RM; Chicea L
    Medicine (Baltimore); 2021 May; 100(18):e25832. PubMed ID: 33950993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group.
    Hermine O; Mariette X; Porcher R; Djossou F; Nguyen Y; Arlet JB; Savale L; Diehl JL; Georgin-Lavialle S; Cadranel J; Pialoux G; Lacombe K; Mekinian A; Gros H; Lescure X; Ghosn J; Coupez E; Grapin K; Rapp C; Michel M; Lecapitaine AL; Michot JM; Costedoat-Chalumeau N; Nguyen LBL; Semerano L; Raffi F; Aguillar C; Rouzaud C; Gottenberg JE; Hansmann Y; Bienvenu B; London J; Fantchou FS; Ackermann F; Gros A; Morel A; Gambier N; Sène D; Mégarbane B; Azoulay E; Bureau S; Dougados M; Emmerich J; Fartoukh M; Guidet B; Humbert M; Mahevas M; Pène F; Schlemmer F; Pourcher-Martinez V; Tibi A; Baron G; Perrodeau E; Baron S; Steg G; Yazdapanah Y; Simon T; Resche-Rigon M; Tharaux PL; Ravaud P
    EClinicalMedicine; 2022 Apr; 46():101362. PubMed ID: 35350097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study.
    Zarębska-Michaluk D; Jaroszewicz J; Rogalska M; Martonik D; Pabjan P; Berkan-Kawińska A; Bolewska B; Oczko-Grzesik B; Kozielewicz D; Tudrujek-Zdunek M; Kowalska J; Moniuszko-Malinowska A; Kłos K; Rorat M; Leszczyński P; Piekarska A; Polańska J; Flisiak R
    J Inflamm Res; 2021; 14():3359-3366. PubMed ID: 34295173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.
    Rubio-Rivas M; Forero CG; Mora-Luján JM; Montero A; Formiga F; Homs NA; Albà-Albalate J; Sánchez L; Rello J; Corbella X
    Pharmacotherapy; 2021 Nov; 41(11):884-906. PubMed ID: 34558742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID-19 Pneumonia: A Single-Center Retrospective Study.
    Radulescu A; Istrate A; Muntean M
    Int J Infect Dis; 2022 Apr; 117():1-7. PubMed ID: 35093528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes.
    Al-Baadani A; Eltayeb N; Alsufyani E; Albahrani S; Basheri S; Albayat H; Batubara E; Ballool S; Al Assiri A; Faqihi F; Musa AB; Robert AA; Alsherbeeni N; Elzein F
    J Infect Public Health; 2021 Aug; 14(8):1021-1027. PubMed ID: 34153727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness.
    Rubio-Rivas M; Ronda M; Padulles A; Mitjavila F; Riera-Mestre A; García-Forero C; Iriarte A; Mora JM; Padulles N; Gonzalez M; Solanich X; Gasa M; Suarez-Cuartin G; Sabater J; Perez-Fernandez XL; Santacana E; Leiva E; Ariza-Sole A; Dallaglio PD; Quero M; Soriano A; Pasqualetto A; Koo M; Esteve V; Antoli A; Moreno-Gonzalez R; Yun S; Cerda P; Llaberia M; Formiga F; Fanlo M; Montero A; Chivite D; Capdevila O; Bolao F; Pinto X; Llop J; Sabate A; Guardiola J; Cruzado JM; Comin-Colet J; Santos S; Jodar R; Corbella X
    Int J Infect Dis; 2020 Dec; 101():290-297. PubMed ID: 33035673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of tocilizumab therapy in severe or critical COVID-19 patients: A retrospective cohort, single-centre study.
    Abdelnaby H; Aboelhassan W; Al-Jarallah M; Rajan R; Dashti R; Zhanna KD; Alsaber AR; Abd El-Aleem A; Ashry I; Abdullah M; Mahmoud Fouad A
    Trop Med Int Health; 2021 Dec; 26(12):1689-1699. PubMed ID: 34601803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis.
    Alkofide H; Almohaizeie A; Almuhaini S; Alotaibi B; Alkharfy KM
    Int J Infect Dis; 2021 Sep; 110():320-329. PubMed ID: 34273515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and effectiveness of tocilizumab in older adult critically ill patients with COVID-19: a multicenter, cohort study.
    Korayem GB; Aljuhani O; Altebainawi AF; Shaya AIA; Alnajjar LI; Alissa A; Aldhaeefi M; Kensara R; Al Muqati H; Alhuwahmel A; Alhuthaili O; Vishwakarma R; Aldardeer N; Eljaaly K; Alharbi A; Harbi SA; Katheri AA; Bekairy AMA; Aljedai A; Al Sulaiman K
    Int J Infect Dis; 2022 Sep; 122():252-259. PubMed ID: 35605948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
    Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
    J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab.
    Rashad A; Mousa S; Nafady-Hego H; Nafady A; Elgendy H
    Sci Rep; 2021 Apr; 11(1):8816. PubMed ID: 33893337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial of adding Tocilizumab to standard care in critical forms of Covid-19 pneumonia: Study on paired series.
    Trifi A; Abdennebi C; Mehdi A; Ben Romdhane K; Blel Y; Daly F; Zakhama B; Mestiri T; Abdellatif S; Ben Lakhal S
    Tunis Med; 2022 avril; 100(4):309-312. PubMed ID: 36155902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study.
    López-Medrano F; Pérez-Jacoiste Asín MA; Fernández-Ruiz M; Carretero O; Lalueza A; Maestro de la Calle G; Caro JM; de la Calle C; Catalán M; García-García R; Martínez-López J; Origüen J; Ripoll M; San Juan R; Trujillo H; Sevillano Á; Gutiérrez E; de Miguel B; Aguilar F; Gómez C; Silva JT; García-Ruiz de Morales D; Saro-Buendía M; Marrero-Sánchez Á; Chiara-Graciani G; Bueno H; Paz-Artal E; Lumbreras C; Pablos JL; Aguado JM;
    Int J Infect Dis; 2021 Apr; 105():487-494. PubMed ID: 33647515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary Infection Risk in Patients With Severe COVID-19 Pneumonia Treated With Tocilizumab.
    Sandhu G; Piraino ST; Piticaru J
    Am J Ther; 2022 May-Jun 01; 29(3):e275-e278. PubMed ID: 35249968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain.
    Chamorro-de-Vega E; Rodriguez-Gonzalez CG; Manrique-Rodríguez S; Lobato-Matilla E; García-Moreno F; Olmedo M; Correa-Rocha R; Valerio M; Aldámiz-Echevarria T; Machado M; Sancho-Gonzalez M; Lopez-Bernaldo-de-Quirós JC; Ruiz-Briones P; Romero-Jiménez R; Sarobe-González C; Gimenez-Manzorro A; Collado-Borrell R; Fernandez-Llamazares CM; Revuelta-Herrero JL; Somoza-Fernandez B; Garcia-Sanchez S; Taladriz-Sender I; Bouza E; Herranz A; Muñoz P; Sanjurjo M
    Expert Rev Clin Pharmacol; 2021 Feb; 14(2):249-260. PubMed ID: 33499687
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review.
    Roomi S; Ullah W; Ahmed F; Farooq S; Sadiq U; Chohan A; Jafar M; Saddique M; Khanal S; Watson R; Boigon M
    J Med Internet Res; 2020 Sep; 22(9):e21758. PubMed ID: 32784192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19.
    San-Juan R; Fernández-Ruiz M; López-Medrano F; Carretero O; Lalueza A; Maestro de la Calle G; Pérez-Jacoiste Asín MA; Bueno H; Caro-Teller JM; Catalán M; de la Calle C; García-García R; Gómez C; Laguna-Goya R; Lizasoáin M; Martínez-López J; Origüen J; Sevillano Á; Gutiérrez E; de Miguel B; Aguilar F; Parra P; Ripoll M; Ruiz-Merlo T; Trujillo H; Pablos JL; Paz-Artal E; Lumbreras C; Aguado JM;
    Int J Infect Dis; 2022 Apr; 117():56-64. PubMed ID: 35081417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.